PROGNOSTIC VALUE OF TELOMERE DNA IN PROSTATE BIOPSY

描述：（申请人的描述） 评估活检材料中肿瘤生长潜力的预后对于 选择合适的治疗方法。 然而，明确 作为预后基础的分子标记是有限的。 端粒DNA 加帽和保护染色体末端串联六碱基核苷酸重复序列， 通常在癌细胞中较短。 这表明端粒长度可能是 肿瘤进展的重要决定因素。 一种新的狭缝印迹法， 测量端粒DNA含量（端粒长度的代表）是由 主要研究者使用肿瘤组织。 该分析的结果表明 乳腺癌中端粒DNA含量的减少与 异倍体（P <0.002）和转移（P <0.05）， 前列腺癌患者的生存率降低（p <0.004）， 疾病复发（p <0.0001）。 在第一阶段，我们将扩大和 完善端粒DNA含量测定，以适应前列腺针芯 活检标本。 在第二阶段，我们将利用该试验进行 前列腺穿刺活检的回顾性病例对照研究。 端粒DNA含量数据将与患者存活率和肿瘤发生率相关。 结果评估，以确定端粒DNA含量的预测价值， 前列腺活检样本。

DESCRIPTION: (Applicant's Description) Assessing prognosis of tumor growth potential in biopsy material is vital to choosing an appropriate therapy in prostate cancer. However, definitive molecular markers on which to base a prognosis are limited. Telomere DNA, the tandem six-base nucleotide repeats that cap and protect chromosome ends, are typically shorter in cancer cells. This suggests that telomere length may be an important determinant of tumor progression. A new slot blot assay which measures Telomere DNA Content (a proxy for telomere length) was developed by the Principal Investigator using tumor tissue. Results of this assay indicate that reduced telomere DNA content in breast cancer is correlated with aneuploidy (p less than 0.002) and metastasis (p less than 0.05) and in prostate cancer with reduced survival (p less than 0.004) and increased disease recurrence (p less than 0.0001). In Phase I, we will extend and refine the telomere DNA content assay to accommodate prostate needle-core biopsy specimens. In Phase II, we will utilize the assay to conduct a retrospective case-control study of archival prostate needle-core biopsies. The telomere DNA content data will be correlated to patient survival and the results evaluated to ascertain the predictive value of telomere DNA content in prostate biopsy samples.